Predisposing Conditions, Management and Prevention of Chronic Kidney Disease - PowerPoint PPT Presentation

1 / 49
About This Presentation
Title:

Predisposing Conditions, Management and Prevention of Chronic Kidney Disease

Description:

Dr FA Arogundade FMCP FWACP, ISN Fellow. Consultant Nephrologist, Obafemi Awolowo University, ... Preventive Nephrology. Primary Prevention ... – PowerPoint PPT presentation

Number of Views:1294
Avg rating:3.0/5.0
Slides: 50
Provided by: drarog
Category:

less

Transcript and Presenter's Notes

Title: Predisposing Conditions, Management and Prevention of Chronic Kidney Disease


1
Predisposing Conditions, Management and
Prevention of Chronic Kidney Disease
  • Dr FA Arogundade FMCP FWACP, ISN Fellow
  • Consultant Nephrologist,
  • Obafemi Awolowo University,
  • Ile-Ife.

2
Basic Anatomy and Physiology
3
(No Transcript)
4
(No Transcript)
5
(No Transcript)
6
(No Transcript)
7
(No Transcript)
8
(No Transcript)
9
Definition of Chronic Kidney Disease
10
Definition of CKD
  • Progressive and persistent deterioration in
    kidney structure and function, ultimately
    resulting in accumulation of nitrogenous waste
    and disruption of acid base homeostasis.
  • In addition, CKD also leads to derangements of
    the kidneys osmoregulatory, metabolic and
    endocrine functions.
  • Now CKD can be staged (KDOQI)

11
Staging of CKD
Stage 1
Stage 2
Stage 3
GFR gt90
GFR 60-89
Stage 4
GFR 15-29
GFR 30-59
Stage 5
GFR lt15
12
Epidemiology of CKD
13
Prevalence of CKD in Nigeria
  • Prevalence of CRF is largely unknown
  • Conceivably high due to the high prevalence of
    diseases that cause chronic renal failure
  • HYPERTENSION gt 15 in adults
  • DIABETES MELLITUSgt2.5-4.0
  • Chronic inflammation endemicity of malaria,
    Hepatitis B,C, HIV
  • Socio-cultural practices
  • Others

14
Blood pressure distribution in respondents (13.6
had HT, only 3.6 were previously diagnosed)
Diastolic Blood pressure
Systolic Blood pressure
Ulasi et al. Medical screening by NAN, 2005
15
The grading of proteinuria in respondents (19
had proteinuria)
Ulasi et al. Medical screening by NAN, 2005
16
NHANES III16,800
US Population CKD Prevalence Stage number 1
GFRgt90 3.3 5.9 millions 2 89-60 3 5.3 3
59-30 4.3 7.6 4 29-15 0.25 400,000 5 lt15
0.2 345,000 Total 11 19.2
Garg AX et al. Albuminuria and renal
insufficiency prevalence guides
population screening results from the NHANES
III. Kidney Int 2002 61 2165 2175.
17
AusDiab11,247
  • Population-based cross-sectional study to
    determine the prevalence of DM,Obesity,CVD Risk
    factors,and Indicators of Kidney disease in
    Australian adults
  • 11,247 Participants
  • Renal impairment 9.7
  • Haematuria 3.7
  • Albuminuria 6
  • Proteinuria 0.6
  • Total 16

Chadban et al, Prevalence of kidney damage in
Australian adults The AusDiab Kidney Study. J
Am Soc Nehrol 2003, 14 S131 S138.
18
Hospital Data
  • CRF accounts for 812 of hospital medical
    admissions
  • CRF is a leading cause of mortality among adults
  • Sentinel study based on available hospital data
  • Prevalence of 300-400 per million population

Akinsola, 1989 Kadiri et al 1997 Akinsola et
al, 2004. Arogundade et al 2005
19
(No Transcript)
20
(No Transcript)
21
NHANES 4
Aus-Diab 9.7
NHANES 96
Aus-Diab 90.3
22
Documented causes in Nigeria
  • Hypertension
  • Benign
  • Malignant
  • Chronic glomerulonephritis
  • Causes unknown in the majority
  • Occurs post-infection
  • Parasite malaria
  • Bacteria sore throat or skin infections
  • Helminths Schistosoma, Filaria
  • Viruses - Hepatitis B, C, HIV
  • Fungal
  • Toxins Bleaching creams / soap

23
Other documented causes in Nigeria
  • Diabetes Mellitus
  • Chronic urinary tract infection
  • Obstructive Uropathies
  • Drugs Analgesic abuse
  • Inherited kidney disease-ADPKD
  • Connective Tissue Disease - SLE, RA
  • Others

24
Arogundade et al, 2005
25
Management of CKD
26
Objectives of Clinical Evaluation
  • Establishing that there is CKD
  • Defining the likely aetiology
  • Determining occurrence/presence of complications
  • Assessing prognosis and survival

27
Clinical Evaluation Hx Examination
  • Polyuria Nocturia
  • Frothiness of urine
  • Oliguria
  • Symptoms of prostatism
  • Features of uraemia
  • Use of Analgesics, Hg containing creams/soaps,
    other drugs, local herbs
  • Past Medical Hx HT, DM, Body Swelling etc.
  • Family Hx Renal Ds,
  • Social Hx Alcohol, Smoking

28
Clinical Evaluation Hx Examination
  • Presence of HT
  • Presence of oedema
  • Presence of Pallor
  • Presence of Uraemic features
  • Presence of heart failure
  • Presence of retinopathy

29
Investigations
  • Blood
  • Chemistry
  • E/U/Cr
  • Ca, Po4,
  • Alb, Chol, lipid profile
  • Haemogram
  • Blood cell counts
  • Serology
  • Clotting profile
  • Urine
  • Microscopy
  • Chemistry
  • Full urinalysis
  • 24 Hour profile
  • Imaging
  • USS
  • CXR
  • ECHO

30
Management
  • Conservative
  • Control of risk factors
  • Modifiable
  • Non modifiable
  • RRT
  • PD
  • HD
  • Transplant

31
Risk Factors/Markers for progressive CKD
alcohol
CKD
Proteinuria
Smoking
Cal-phos
Card.VD
Race
Infectns
Hypertension
Gender
Anaemia
Weight
CKD
Ageing
Lipids
Nutrition
DM
32
JNC VII Classification and management of BP for
adults
33
  • 75.7 had hypoalbuminaemia ( mean SD for serum
    albumin 29.5 7.2 g/L).
  • 88.9 had anaemia (Packed Cell Volume,PCV lt33)
    Mean SD 24.2 7.0).
  • Arogundade et al , 2005

34
CKD Prevention Modifiable risk factors
Proteinuria lt1g/d
PCV 33-36
Alcohol
DM lt7
Hypertension lt125/75
ALB
Lipids lt5
Weight
Smoking STOP
Ca-Ph lt4.5
CVD Protection
35
Choice of Antihypertensives
  • Regimens that include angiotensin-converting
    enzyme inhibitors (ACEIs) are more effective than
    regimens that do not include ACEIs in slowing
    progression of both diabetic and non-diabetic
    kidney disease.
  • Combination therapy of ACEI and angiotensin
    receptor blocker (ARB) slows progression of both
    diabetic and non-diabetic kidney disease more
    effectively than either single agent.

36
Choice of Antihypertensives
  • ACEIs appear to be more effective than
    beta-blockers and dihydropyridine calcium channel
    blockers in slowing progressive kidney disease.
  • Beta-blockers may be more effective in slowing
    progression than dihydropyridine calcium channel
    blockers, especially in the presence of
    proteinuria.

37
(No Transcript)
38
(No Transcript)
39
(No Transcript)
40
(No Transcript)
41
(No Transcript)
42
Prevention
43
Preventive Nephrology
  • Primary Prevention
  • Aims at preventing kidney disease from occurring
    at all
  • Calls for knowledge of
  • risk factors that predispose to renal disease
  • risk factors that initiate renal damage.
  • modification, removal, or avoidance of factors.
  • development of a positive health seeking attitude
    and behaviour
  • Secondary Prevention
  • Aims at identifying factors that aid or hasten
    progression of kidney disease and/or accelerate
    loss of kidney function, and preventing or
    removing such factors. While a few of these
    factors are not modifiable, majority of them
    could be modified, controlled or completely
    avoided.
  • Tertiary Prevention

44
Risk Factors/Markers for progressive CKD
CKD
Proteinuria
Smoking
Race
Card.VD
Infectns
Cal-phos
Hypertension
Ageing
Anaemia
alcohol
Weight
CKD
DM
Gender
Lipids
Nutrition
Non Modifiable
Modifiable
45
CKD Prevention Modifiable risk factors
Proteinuria lt1g/d
PCV 33-36
Alcohol
DM lt7
Hypertension lt125/75
ALB
Lipids lt5
Weight
Smoking STOP
Ca-Ph lt4.5
CVD Protection
46
Tertiary Prevention
Proteinuria lt1g/d
PCV 33-36
Alcohol
DM lt7
Hypertension lt125/75
ALB
Lipids lt5
Weight
Smoking STOP
Ca-Ph lt4.5
47
Tertiary Prevention Contd
  • Control of HT
  • Use of EPO Parenteral Iron
  • Use of Vit D analogues
  • Use of Phosphate sequestering agents
  • Control of hyperlipidaemia
  • Control of Infections
  • Control of Heart Failure

48
When do we refer to Nephrologists
  • CKD 4 5
  • Resistant HT
  • Persistent proteinuria / haematuria
  • Difficulty achieving Bld sugar control
  • Established CKD
  • Uraemia
  • Heart failure
  • Anaemia

49
Thank you for listening
Write a Comment
User Comments (0)
About PowerShow.com